<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03782792</url>
  </required_header>
  <id_info>
    <org_study_id>1368-0013</org_study_id>
    <secondary_id>2017-004231-37</secondary_id>
    <nct_id>NCT03782792</nct_id>
  </id_info>
  <brief_title>A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis</brief_title>
  <official_title>Effisayil™ 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of BI 655130 in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients
      with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to
      severe intensity
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A GPPGA pustulation sub-score of 0 indicating no visible pustules at Week 1</measure>
    <time_frame>Up to Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 at Week 1</measure>
    <time_frame>Up to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI) 75 at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Pain Visual Analog Scale (VAS) score at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Psoriasis Symptom Scale (PSS) score at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 indicating no visible pustules at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) from baseline at Week 4</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 1</measure>
    <time_frame>Up to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) from baseline at Week 1</measure>
    <time_frame>Up to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Generalized Pustular Psoriasis</condition>
  <arm_group>
    <arm_group_label>Spesolimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spesolimab</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Spesolimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with GPPGA of 0 or 1 and a known and documented history of GPP per European
             Rare And Severe Psoriasis Expert Network (ERASPEN) criteria regardless of IL36RN
             mutation status, with previous evidence of fever, and/or asthenia, and/or myalgia,
             and/or elevated C-reactive protein, and/or leucocytosis with peripheral blood
             neutrophilia (above ULN) OR

             -- Patients with an acute flare of moderate to severe intensity meeting the (ERASPEN)
             criteria of GPP with a known and documented history of GPP (per ERASPEN criteria)
             regardless of IL36RN mutation status, with previous evidence of fever, and/or
             asthenia, and/or myalgia, and/or elevated C-reactive protein, and/or leucocytosis with
             peripheral blood neutrophilia (above ULN)

          -  Male or female patients, aged 18 to 75 years at screening.

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with ICH GCP and local legislation prior to start of any screening
             procedures.

          -  Women of childbearing potential must be ready and able to use highly effective methods
             of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per
             year when used consistently and correctly. Note: A woman is considered of childbearing
             potential, i.e. fertile, following menarche and until becoming postmenopausal unless
             permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral
             salpingectomy and bilateral oophorectomy. Tubal ligation is not a method of permanent
             sterilization. A postmenopausal state is defined as no menses for 12 months without an
             alternative medical cause

          -  Further inclusion criteria apply

        Exclusion Criteria:

          -  Patients with SAPHO (Synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome.

          -  Patients with primary erythrodermic psoriasis vulgaris.

          -  Patients with primary plaque psoriasis vulgaris without presence of pustules or with
             pustules that are restricted to psoriatic plaques.

          -  Drug-triggered Acute Generalized Exanthematous Pustulosis (AGEP).

          -  Immediate life-threatening flare of GPP or requiring intensive care treatment,
             according to the investigator's judgement. Life-threatening complications mainly
             include, but are not limited to, cardiovascular/cytokine driven shock, pulmonary
             distress syndrome, or renal failure.

          -  Severe, progressive, or uncontrolled hepatic disease, defined as &gt;3- fold Upper Limit
             of Normal (ULN) elevation in AST or ALT or alkaline phosphatase, or &gt;2-fold ULN
             elevation in total bilirubin.

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqi Song</last_name>
      <phone>18098876580</phone>
      <email>zxdalian66@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>2nd Affiliated Hosp Zhejiang University College of Medical</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Zheng</last_name>
      <phone>13906520296</phone>
      <email>zhengminbi@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Skin Disease Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yangfeng Ding</last_name>
      <phone>18017336636</phone>
      <email>dingyangfeng@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhua Xu</last_name>
      <phone>13818978539</phone>
      <email>xujinhua2020@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>30052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanzhong Liu</last_name>
      <phone>+8613662162889</phone>
      <email>liuqztjykdxzyy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Beylot-Barry</last_name>
      <phone>+33 (0)5 57 82 25 00</phone>
      <email>marie.beylot-barry@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Bachelez</last_name>
      <phone>+33 (0)1 42 49 98 17</phone>
      <email>herve.bachelez@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuelle-Anne Viguier</last_name>
      <phone>+33 (0)3 26 78 43 43</phone>
      <email>mviguier@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn AöR</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sticherling</last_name>
      <phone>4991318533851</phone>
      <email>Michael.Sticherling@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen AöR</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Pinter</last_name>
      <phone>+49 (69) 63015418</phone>
      <email>Andreas.Pinter@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Schäkel</last_name>
      <phone>+49 (6221) 568511</phone>
      <email>knut.schaekel@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München - Campus Innenstadt</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akimichi Morita</last_name>
      <phone>+81 52 8515511</phone>
      <email>amorita@med.nagoya-cu.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shinichi Imafuku</last_name>
      <phone>+81 92 8011011</phone>
      <email>simafuku.chiken@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical University Hospital</name>
      <address>
        <city>Hokkaido, Asahikawa</city>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaru Honma</last_name>
      <phone>+81 166 652111</phone>
      <email>wanwan@asahikawa-med.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Ibaraki Medical Center</name>
      <address>
        <city>Ibaraki, Inashiki-gun</city>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuhiro Kawachi</last_name>
      <phone>+81 29 8871161</phone>
      <email>kyasuhir@tokyo-med.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Mie, Tsu</city>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi, Sendai</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenshi Yamasaki</last_name>
      <phone>+81 2 27177000</phone>
      <email>kyamasaki@med.tohoku.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Nagano, Matsumoto</city>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eisaku Ogawa</last_name>
      <phone>+81 263 354600</phone>
      <email>ukasie@shinshu-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka, Osaka-sayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shigeto Yanagihara</last_name>
      <phone>+81 72 3660221</phone>
      <email>shigetooo@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hachioji Medical Center</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <zip>193-0998</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukihiko Kato</last_name>
      <phone>+81 42 6655611</phone>
      <email>y-kato@tokyo-med.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo, Itabashi</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideki Fujita</last_name>
      <phone>+81 3 39728111</phone>
      <email>hfuji-tky@umin.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukari Okubo</last_name>
      <phone>+81 3 33426111</phone>
      <email>yukari-o@tokyo-med.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National Univ. Hosp</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Soo Kim</last_name>
      <phone>82 2 2072 4916</phone>
      <email>dockbs@pusan.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Jin Jo</last_name>
      <phone>82 51 240 7338</phone>
      <email>ayin76@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Geol Lee</last_name>
      <phone>+82222282085</phone>
      <email>mglee@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Aminah</name>
      <address>
        <city>Johor Bahru</city>
        <zip>80100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siew Eng Choon</last_name>
      <phone>+60127162118</phone>
      <email>choonse@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <zip>81100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latha Selvarajah</last_name>
      <phone>+60164539301</phone>
      <email>lathaselvarajah@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azura Binti Mohd Affandi</last_name>
      <phone>60326155555 (1540)</phone>
      <email>affandi_azura@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pakar Sultanah Fatimah</name>
      <address>
        <city>Muar</city>
        <zip>84000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Yap</last_name>
      <phone>+60176823538</phone>
      <email>chervil_82@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Permaisuri Bainun</name>
      <address>
        <city>Negeri Perak/Ipoh</city>
        <zip>30450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh Jong Tang</last_name>
      <phone>6052087494 (7491)</phone>
      <email>tangjyhjong@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wooi Chiang Tan</last_name>
      <phone>6042225250</phone>
      <email>tanwooichiang@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Selangor</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benji Teoh</last_name>
      <phone>+60361263333 (ext. 4317)</phone>
      <email>benjiteoh@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Navarini</last_name>
      <phone>+41612654084</phone>
      <email>alexander.navarini@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curdin Conrad</last_name>
      <phone>0041 21 314 1111</phone>
      <email>curdin.conrad@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Chen Ho</last_name>
      <phone>07 7317123 ext 2424</phone>
      <email>jichenho@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10016</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsen Fang Tsai</last_name>
      <phone>886 972651561</phone>
      <email>tftsai@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Dermatology</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bensachee Pattamadilok</last_name>
      <phone>+66 2 3545222</phone>
      <email>bensachee@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Ratchatewi, Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natta Rajatanavin</last_name>
      <phone>+66 2 2011211</phone>
      <email>natta.rama@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Farhat Hached Hospital</name>
      <address>
        <city>Sousse</city>
        <zip>4000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Denguezli</last_name>
      <phone>21655757472</phone>
      <email>denguezli1961@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hedi Chaker Hospital, Department of Dermatology</name>
      <address>
        <city>Tunisia</city>
        <zip>1053</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamida Turki</last_name>
      <phone>+216 74 242 627</phone>
      <email>hamida.turki@rns.tn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Rabta Hospital</name>
      <address>
        <city>Tunis</city>
        <zip>1007</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mourad MOKNI</last_name>
      <phone>216 71 566 885</phone>
      <email>Mourad.mokni@rns.tn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Tunisia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https:// trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link http://trials.boehringer-ingelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

